Eos Energy Enterprises Inc vs Inovio Pharmaceuticals Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.25 (market cap $1.54B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Eos Energy Enterprises Inc is far larger — about 19.6× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| EOSE | INO | |
|---|---|---|
Market Cap | $1.54B | $78.55M |
Sector | Energy | Health |
52-Week High | $19.19 | $2.87 |
52-Week Low | $3.14 | $0.66 |
Enterprise Value | $1.88B | $49.56M |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.24, up 4.69% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 loss per share. Financials reveal significant challenges with negative gross margins of -84.75% and net income margin of -246.76% for 2026, though revenue growth from $114M to $214M year-over-year shows scaling progress.
While analyst consensus targets $7.75 (83% upside), the stock faces substantial fundamental risks including negative profitability, shareholder litigation investigation, and high debt-to-asset ratio of 91.87%. The company's energy storage technology and growing backlog provide potential, but execution risks and cash burn require careful monitoring for investors considering this speculative growth play.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →